

Supplementary material for:

Clinical genetic risk variants inform a functional protein interaction network for tetralogy of Fallot

Miriam S. Reuter, Rajiv R. Chaturvedi, Rebekah K. Jobling, Giovanna Pellecchia, Omar Hamdan, Wilson W.L. Sung, Thomas Nalpathamkalam, Pratyusha Attaluri, Candice K. Silversides, Rachel M. Wald, Christian R. Marshall, Simon Williams, Bernard D. Keavney, Bhooma Thiruvahindrapuram, Stephen W. Scherer, Anne S. Bassett

Supplementary methods

Exome sequencing data

We analyzed the exome sequencing data of a multi-centre cohort of children and adults with tetralogy of Fallot (TOF). Exome sequencing had been performed at the McGill University/Genome Quebec Innovation Centre (MUGQIC; Montreal, Canada), and the methodology is described in detail in the supplementary information of Page et al.¹. Briefly, exome capture was performed using Agilent SureSelectXT Human All Exon 50 Mb version 4 kit (Agilent). Trimming of paired-end sequencing reads (100 bp), using Trimmomatic, and read mapping with removal of duplicate reads (BWA-MEM algorithm²) were done at the McGill Genome Centre.

We downloaded 829 bam files from the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega>; EGAS00001003302)¹. We excluded 18 data files that were: corrupted (n = 2), aligned to a different reference genome: bwa VN:0.7.6a-r433, b37 (n = 9), or found to be identical to other samples in the cohort (n = 7). We studied the resulting n = 811 unique exome sequencing datasets, aligned to the bwa VN:0.7.4-r385, hg19 reference genome.

Variant calling and annotation

The genome analysis tool kit (GATK v3.7; GATK Best Practices recommendations^{3, 4}) was used for base quality score recalibration and indel realignment prior to variant calling using the HaplotypeCaller. Hard-filters were applied to the small nucleotide variants (SNVs) (QD < 2.0 || FS > 60.0 || MQ < 40.0 || MQRankSum < -12.5 || ReadPosRankSum < -8.0 || SOR > 3.0) and insertions/deletions (indels) (QD < 2.0 || FS > 200.0 || ReadPosRankSum < -20.0 || SOR > 10.0). Variant calls were annotated using a custom pipeline developed at TCAG based on ANNOVAR⁵.

Variant assessments

We analyzed the exome sequencing dataset for rare (minor allele frequencies <0.1%) sequence variants (substitutions and small insertions/deletions), prioritizing genes associated with congenital heart disease (<http://chdgene.victorchang.edu.au/>), other cardiac disorders, or multi-systemic disorders (<https://www.omim.org/>, <https://research.nhgri.nih.gov/CGD/>).

(i) Predicted loss-of-function alleles

We predicted the following as loss-of-function (LoF) or null alleles: frameshift insertions, deletions or substitutions; substitutions creating a premature stop codon; and alterations of the intronic dinucleotide adjacent to a coding-exonic splice junction.

(ii) Allele frequency and control databases

Overall and population-specific allele frequencies for SNVs and small indels were derived from 1000 Genomes (African, American, East Asian, European, South Asian; <http://www.internationalgenome.org/>), ExAC (African, American, East Asian, Finnish, Non-Finnish Europeans, South Asians, Others; <http://exac.broadinstitute.org/>)⁶, and gnomAD (African, American, Ashkenazi Jewish, East Asian, Finnish, Non-Finnish Europeans, South Asians, Others; <http://gnomad.broadinstitute.org/>)⁷.

(iii) Disease gene and variant databases

Online Mendelian Inheritance in Man (OMIM; <https://www.omim.org/>) and CHDgene (<http://chdgene.victorchang.edu.au/>) were used as disease gene databases. The Human Gene Mutation Database (HGMD; <http://www.hgmd.cf.ac.uk/ac/index.php>) and ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) were used as disease variant databases.

(iv) Emerging candidate genes

We also analyzed for other genes with emerging evidence that they are associated with TOF or other congenital heart defects (<https://pubmed.ncbi.nlm.nih.gov/>). We assessed the available evidence in the literature, in combination with statistical support from the cohort reported here.

(v) Validation of variants

We only report on variants that were covered by read depths of $\geq 10x$. Read alignments for all putative disease-associated variants were manually inspected using IGV (<http://software.broadinstitute.org/software/igv/>).

Pathway enrichment analyses

Genes annotated to ontology terms⁸ were extracted using the Bioconductor R package GO.db v 3.5, while the pathways were built starting from their respective websites (for Reactome⁹ and KEGG¹⁰), and Broad Institute website (for Biocarta) to create a custom gene-set collection. Gene-sets were filtered to retain gene ontology terms with a number of annotated genes between 15 and 1000, while Reactome, KEGG and Biocarta were filtered to retain only pathways with a number of annotated genes between 5 and 500. One-tailed Fisher exact test ($H_a > H_0$) was used to calculate the enrichment p values, using all genes in the filtered collection as the universe. P values and odd ratios are reported in Table S8 (provided as a separate file); the Benjamini-Hochberg procedure was used for the multiple test comparison correction.

Table S1. Exome sequencing coverage statistics.

Included datasets (n = 811)	Mean target coverage per exome	Proportion with coverage $\geq 10x$
Average	107.9x	98.4%
Median	111.0x	98.6%
Range	33.4x - 158.6x	90.8% - 99.6%

Supplementary results**Table S2. Pathogenic/likely pathogenic risk variants for congenital heart defects (CHD), identified in a cohort of 811 probands with tetralogy of Fallot (n = 40 loss-of-function, n = 10 missense in 23 genes; results summarized in Figure 1).**

Sample	Gene	Variant	Variant type	MAF	Disease mechanism/evidence	OMIM-P #	OMIM disease (inheritance) or supporting literature
B009FTV ^a	<i>FLT4</i> (NM_182925.4)	c.2758C>T, p.(Gln920*)	LOF	4.18E-06	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
B009FV1_R ^a	<i>FLT4</i> (NM_182925.4)	c.2300-1G>C, p.?	LOF	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
B00BOEY_R ^a	<i>FLT4</i> (NM_182925.4)	c.1267dupC, p.(Gln423Profs*4)	LOF	4.11E-06	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
B00B0HD ^a	<i>FLT4</i> (NM_182925.4)	c.2849_2850+18del CGCAGGCCGCCGCTCACCG, p.?	LOF	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
B00BOKK ^a	<i>FLT4</i> (NM_182925.4)	c.1083C>A, p.(Tyr361*)	LOF	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
B00B0O8 ^a	<i>FLT4</i> (NM_182925.4)	c.2686G>T, p.(Glu896*)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00B0PK ^a	<i>FLT4</i> (NM_182925.4)	c.2714delA, p.(Asn905Thrfs*21)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00B0QE_R ^a	<i>FLT4</i> (NM_182925.4)	c.2559dupC, p.(Gly854Argfs*21)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00B16G ^a	<i>FLT4</i> (NM_182925.4)	c.3002-1G>A, p.?	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00BDV3_R ^a	<i>FLT4</i> (NM_182925.4)	c.3376C>T, p.(Gln1126*)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00BDV4 ^a	<i>FLT4</i> (NM_182925.4)	c.3002-2A>G, p.?	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00BET4 ^a	<i>FLT4</i> (NM_182925.4)	c.1107C>G, p.(Tyr369*)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00BETB ^a	<i>FLT4</i> (NM_182925.4)	c.1902_1906dupCACGC, p.(Leu636Profs*5)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00DKZL_R ^a	<i>FLT4</i> (NM_182925.4)	c.3091C>T, p.(Arg1031*)	LOF	0	FLT4 haploinsufficiency	616589	Congenital heart defects, multiple types (AD)
B00BOK9	<i>NOTCH1</i> (NM_017617.3)	c.1045delA, p.(Thr349Profs*282)	LOF	2.07E-05	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00B0O5 ^a	<i>NOTCH1</i> (NM_017617.3)	c.5385-2delA, p.?	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)

B00BOSE ^{a,d}	<i>NOTCH1</i> (NM_017617.3)	c.1342C>T, p.(Arg448*)	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00BOSS ^a	<i>NOTCH1</i> (NM_017617.3)	c.344delG, p.(Gly115Alafs*8)	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00BDT8 ^a	<i>NOTCH1</i> (NM_017617.3)	c.3966delC, p.(Cys1322Trpfs*123)	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00BEAA ^a	<i>NOTCH1</i> (NM_017617.3)	c.5197C>T, p.(Gln1733*)	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00DLD1 ^a	<i>NOTCH1</i> (NM_017617.3)	c.440delA, p.(Asn147Thrfs*130)	LOF	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B009FQG_R ^a	<i>NOTCH1</i> (NM_017617.3)	c.599G>T, p.(Gly200Val)	Missense	0	De novo in Page et al. ¹ , found in two unrelated individuals	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B00BOKM ^a	<i>NOTCH1</i> (NM_017617.3)	c.599G>T, p.(Gly200Val)	Missense	0	De novo in Page et al. ¹ , found in two unrelated individuals	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B009G03_R ^a	<i>NOTCH1</i> (NM_017617.3)	c.5624A>G, p.(Asn1875Ser)	Missense	0	De novo, reduced Notch signaling in Page et al. ¹	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B009G7N ^a	<i>NOTCH1</i> (NM_017617.3)	c.1820G>A, p.(Cys607Tyr)	Missense	0	Reduced Notch signaling in Page et al. ¹ , cysteine substitution in EGF domain	616028, 109730	Adams-Oliver syndrome (AD) ^b , Aortic valve disease (AD)
B009FUJ_R	<i>JAG1</i> (NM_000214.2)	c.1984delG, p.(Ala662Profs*81)	LOF	0	JAG1 haploinsufficiency	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD) ^b
B00BOGY	<i>JAG1</i> (NM_000214.2)	c.2639_2640delGT, p.(Cys880*)	LOF	0	JAG1 haploinsufficiency	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD) ^b
B00BOIL	<i>JAG1</i> (NM_000214.2)	c.2372+2T>G, p.?	LOF	0	JAG1 haploinsufficiency	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD) ^b
B00BOKQ	<i>TBX1</i> (NM_080646.1)	c.549delG, p.(Lys184Argfs*24)	LOF	0	TBX1 haploinsufficiency	187500	Tetralogy of Fallot (AD)
B00DL8V	<i>TBX1</i> (NM_080646.1)	c.908+1G>A, p.?	LOF	0	TBX1 haploinsufficiency	187500	Tetralogy of Fallot (AD)
B00BORO	<i>GATA6</i> (NM_005257.6)	c.1502C>A, p.(Ser501*)	LOF	0	GATA6 haploinsufficiency	187500, 600001	Tetralogy of Fallot (AD), Pancreatic agenesis and congenital heart defects (AD) ^b
B00BEBP	<i>GATA6</i> (NM_005257.6)	c.1367G>A, p.(Arg456His)	Missense	0	De novo in Allen et al. ¹¹	187500, 600001	Tetralogy of Fallot (AD), Pancreatic agenesis and congenital heart defects (AD) ^b
B009FO4_R	<i>KAT6A</i> (NM_006766.3)	c.1506delT, p.(Asp503Ilefs*42)	LOF	0	KAT6A haploinsufficiency	616268	Arboleda-Tham syndrome (AD) ^b
B009FO7 ^c	<i>PSMD12</i> (NM_002816.5)	c.430C>T, p.(Arg144*)	LOF	0	PSMD12 haploinsufficiency	617516	Stankiewicz-Isidor syndrome (AD) ^b
B009G6B	<i>CSNK2A1</i> (NM_177559.2)	c.131_132delAA, p.(Lys44Ilefs*5)	LOF	0	CSNK2A1 haploinsufficiency	617062	Okur-Chung neurodevelopmental syndrome (AD) ^b
B00BOKC	<i>ATRX</i> (NM_000489.5)	c.3736+1G>T, p.?	LOF	0	ATRX deficiency	301040	Alpha-thalassemia/mental retardation syndrome (XLD) ^b

B00BEAD_R	<i>NF1</i> (NM_000267.3)	c.5206-1G>C, p.?	LOF	0	NF1 haploinsufficiency	162200	Neurofibromatosis, type 1 (AD) ^b
B00DLD6	<i>CHD7</i> (NM_017780.4)	c.7160C>G, p.(Ser2387*)	LOF	0	CHD7 haploinsufficiency	214800	CHARGE syndrome (AD) ^b
B009FO7 ^c	<i>ASXL1</i> (NM_015338.6)	c.2728C>T, p.(Gln910*)	LOF	0	ASXL1 haploinsufficiency	605039	Bohring-Opitz syndrome (AD) ^b
B009G7S	<i>GATAD2B</i> (NM_020699.4)	c.520C>T, p.(Arg174*)	LOF	0	GATAD2B haploinsufficiency ¹²	615074	GAND syndrome (AD) ^b
B009G79_R	<i>PIK3CA</i> (NM_006218.4)	c.2809_2810del, p.F937fs	LOF	0	PIK3CA haploinsufficiency ¹³	602501	Megalencephaly-capillary malformation-polymicrogyria syndrome (postzygotic variants) ^b
B009G7Z	<i>RASA1</i> (NM_002890.2)	c.2150_2151delTC, p.(Ile717Asnfs*8)	LOF	0	RASA1 haploinsufficiency ¹⁴	608354	Capillary malformation-arteriovenous malformation (AD) ^b
B00BOIX	<i>NODAL</i> (NM_018055.5)	c.692G>A, p.(Trp231*)	LOF	4.06E-06	NODAL haploinsufficiency ^{15, 16}	270100	Heterotaxy (AD) ^b
B00DKWE	<i>ARHGAP31</i> (NM_020754.4)	c.2047C>T, p.(Gln683*)	LOF	0	ARHGAP31 haploinsufficiency	100300	Adams-Oliver syndrome (AD) ^b
B00DKW1	<i>SMAD2</i> (NM_005901.6)	c.998-2A>C, p.?	LOF	0	SMAD2 haploinsufficiency	NA	17, 18, b
B00BOSO	<i>DLL4</i> (NM_019074.4)	c.949A>C, p.(Thr317Pro)	Missense	0	De novo in Meester et al. ¹⁹	616589	Adams-Oliver syndrome (AD) ^b
B009FV4	<i>RAF1</i> (NM_001354689.3)	c.1532C>T, p.(Thr511Ile)	Missense	0	RAF1 gain-of-function, curated by ClinVar expert panel	611553	Noonan syndrome (AD) ^b
B009FVM_R	<i>CACNA1C</i> (NM_001167625.1)	c.1216G>A, p.(Gly406Arg)	Missense	0	De novo in Napolitano et al. ²⁰	601005	Timothy syndrome (AD) ^b
B00BOLX	<i>LZTR1</i> (NM_006767.4)	c.742G>A, p.(Gly248Arg)	Missense	0	De novo or segregating in Chinton et al. ²¹	616564	Noonan syndrome (AD) ^b
B00BDTA	<i>EP300</i> (NM_001429.4)	c.4783T>G, p.(Phe1595Val)	Missense	0	De novo in Retterer et al. ²²	613684	Rubinstein-Taybi syndrome (AD) ^b

All variants were heterozygous. Variant counts as displayed in Figure 1 (confirmed CHD genes). Minor allele frequencies (MAF) were derived from gnomAD_exomes_All.

^a Variant also reported in Page et al.¹. Note: Reporting of *NOTCH1*, *FLT4* and other variants may differ on the basis of differences in methodology of the current study to that of Page et al. ¹, e.g., nomenclature, frequency cut-offs, in silico prediction methods, exclusion of samples (see discussion in manuscript text).

^b Multi-systemic, or potentially multi-systemic condition.

^c Individual B009FO7 had two likely pathogenic variants, one in *PSMD12* and one in *ASXL1*, both associated with an increased risk for CHD.

^d Individual B00BOSE had two likely pathogenic/pathogenic variants, one in *NOTCH1* and one in *MYBPC3* with potential implications for cardiovascular outcome (Table S7).

AD, autosomal dominant; LOF, loss-of-function; NA, Not available; XLD, X-linked dominant.

Table S3. Loss-of-function variants in emerging TOF/CHD candidate genes, identified in three or more individuals in the cohort studied (and with statistical support, as presented in Figure 1 and Results).

Sample	Gene	Variant	Variant type	MAF	Disease mechanism/evidence	OMIM-P #	OMIM disease (inheritance) or supporting literature
B009FP4	<i>KDR</i> (NM_002253.2)	c.3580_3581delCT, p.(Leu1194Alafs*15)	LOF	0	KDR haploinsufficiency	NA	23, 24
B00B0PI_R	<i>KDR</i> (NM_002253.2)	c.2605delA, p.(Met869Cysfs*2)	LOF	0	KDR haploinsufficiency	NA	23, 24
B00BQTD	<i>KDR</i> (NM_002253.2)	c.3170delC, p.(Pro1057Glufs*13)	LOF	0	KDR haploinsufficiency	NA	23, 24
B00DKWY	<i>KDR</i> (NM_002253.2)	c.2373+1G>A, p.?	LOF	0	KDR haploinsufficiency	NA	23, 24
B009FQA_R	<i>IQGAP1</i> (NM_003870.3)	c.650-2A>T, p.?	LOF	1.33E-05	<i>IQGAP1</i> haploinsufficiency	NA	23, 25, 26
B00B1D6	<i>IQGAP1</i> (NM_003870.3)	c.1393dupA, p.(Arg465Lysfs*26)	LOF	0	<i>IQGAP1</i> haploinsufficiency	NA	23, 25, 26
B009FOS_R	<i>IQGAP1</i> (NM_003870.3)	c.1150C>T, p.(Gln384*)	LOF	4.15E-06	<i>IQGAP1</i> haploinsufficiency	NA	23, 25, 26
B009FNV	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B009FTS_R	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B00B0H7	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B00B0JI	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B00BDT4	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B00BDTU	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B00DLOL	<i>GDF1</i> (NM_001492.4)	c.681C>A, p.(Cys227*)	LOF	9.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)
B009GOC	<i>GDF1</i> (NM_001492.4)	c.1047_1050delCTTT, p.(Phe349Leufs*35)	LOF	1.00E-04 ^a	<i>GDF1</i> haploinsufficiency ²⁷	613854	Congenital heart defects, multiple types (AD)

All variants were heterozygous. Variant counts as displayed in Figure 1 (candidate genes).

^a Minor allele frequencies (MAF) for *GDF1* were derived from gnomAD_genomes_Non-Finnish Europeans. A comprehensive assessment of the *GDF1* locus could not be performed due to insufficient coverage (defined as read depths <10x; supplementary methods). Other MAF were derived from gnomAD_exomes_All.

LOF, loss-of-function; NA, Not available.

Table S4. Pathogenic/likely pathogenic and candidate loss of function variants (n = 17) in 8 genes observed in a published independent cohort of 424 probands with tetralogy of Fallot (Jin et al. ²⁸).

Sample	Gene	Variant	MAF	Disease mechanism/evidence	OMIM-P #	OMIM disease (inheritance) or supporting literature
1-00645	<i>FLT4</i> (NM_182925.4)	c.2206C>T, p.(Gln736*)	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-01795	<i>FLT4</i> (NM_182925.4)	c.1088dupC, p.(Pro364Alafs*63)	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-00788	<i>FLT4</i> (NM_182925.4)	c.503_506delCGCT, p.(Thr168Serfs*76)	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-05967	<i>FLT4</i> (NM_182925.4)	c.89delC, p.(Pro30Argfs*3)	4.05E-05	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-04970	<i>FLT4</i> (NM_182925.4)	c.1083C>G, p.(Tyr361*)	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-06642	<i>FLT4</i> (NM_182925.4)	c.2804delT, p.(Leu935Profs*72)	0	FLT4 haploinsufficiency	618780	Congenital heart defects, multiple types (AD)
1-03410	<i>FLT4</i> (NM_182925.4)	c.89delC, p.(Pro30Argfs*3)	4.05E-05	FLT4 haploinsufficiency, de novo	618780	Congenital heart defects, multiple types (AD)
1-03825	<i>FLT4</i> (NM_182925.4)	c.2844_2845delCT, p.(Cys949Argfs*53)	0	FLT4 haploinsufficiency, de novo	618780	Congenital heart defects, multiple types (AD)
1-00305	<i>NOTCH1</i> (NM_017617.3)	c.273_277delGGGCT, p.(Gly92Leufs*49)	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^d , Aortic valve disease (AD)
1-00692	<i>NOTCH1</i> (NM_017617.3)	c.1800_1801dupCG, p.(Glu601Alafs*31)	0	NOTCH1 haploinsufficiency	616028, 109730	Adams-Oliver syndrome (AD) ^d , Aortic valve disease (AD)
1-02338	<i>NOTCH2</i> (NM_024408.3)	c.4299delA, p.(Ala1434Leufs*119)	0	NOTCH2 haploinsufficiency	610205	Alagille syndrome (AD)
1-00534	<i>CHD7</i> (NM_017780.3)	c.4795C>T, p.(Gln1599*)	0	CHD7 haploinsufficiency, de novo	214800	CHARGE syndrome (AD)
1-08360	<i>CHD7</i> (NM_017780.3)	c.4393C>T, p.(Arg1465*)	0	CHD7 haploinsufficiency, de novo	214800	CHARGE syndrome (AD)
1-04135	<i>MEIS2</i> (NM_170675.4)	c.383delA, p.(Lys128Serfs*19)	0	MEIS2 haploinsufficiency, de novo	600987	Cleft palate, cardiac defects, and mental retardation (AD)
1-00141	<i>NAA15</i> (NM_057175.3)	c.2282C>A, p.(Ser761*)	0	NAA15 haploinsufficiency, de novo	617787	Mental retardation (AD)
1-08084	<i>RPL5</i> (NM_000969.3)	c.67C>T, p.(Arg23*)	0	RPL5 haploinsufficiency, de novo	612561	Diamond-Blackfan anemia (AD)
1-07375	<i>KDR</i> (NM_002253.2)	c.1585A>T, p.(Lys529*)	0	KDR haploinsufficiency	NA	^{23, 24}

Variants were extracted from variant lists in Jin et al., supplementary Tables S7 and S9²⁸, and interpreted according to consensus guidelines²⁹. This approach resulted in a lower yield, compared to the re-analysis of raw exome files from Page et al.¹ (Tables S2 and S3). Minor allele frequencies (MAF) were derived from gnomAD_exomes_All.

NA, not available.

Table S5. Additional rare variants, meeting criteria for predicted deleterious variants of uncertain significance (n = 24 loss-of-function, n = 47 missense, n = 9 other) in CHD-relevant genes (n = 19) or candidate genes (n = 8).

Sample	Gene	Variant	Variant type	MAF	Annotation	OMIM-P #	OMIM disease (inheritance) or supporting literature
VUS in CHD-relevant genes (OMIM, http://chdgene.victorchang.edu.au/)							
BOODLES ^a	<i>FLT4</i> (NM_182925.4)	c.4011delT, p.(Tyr1337*)	Other VUS (premature stopcodon in the last exon)	0	NA	618780	Congenital heart defects, multiple types (AD)
BOOBOKK ^{a,b}	<i>FLT4</i> (NM_182925.4)	c.781G>T, p.(Gly261Cys)	Missense VUS	0	Predicted damaging (CADD 24.3)	618780	Congenital heart defects, multiple types (AD)
BOOBOLF ^a	<i>FLT4</i> (NM_182925.4)	c.153C>G, p.(Cys51Trp)	Missense VUS	0	Predicted damaging (CADD 34)	618780	Congenital heart defects, multiple types (AD)
BOOBDS0	<i>FLT4</i> (NM_182925.4)	c.513G>A, p.(Ser171Ser)	Other VUS (synonymous)	0	Predicted splice effect (CADD 20.5)	618780	Congenital heart defects, multiple types (AD)
BOOBDS9 ^a	<i>FLT4</i> (NM_182925.4)	c.89C>T, p.(Pro30Leu)	Missense VUS	0	Predicted damaging (CADD 25.6)	618780	Congenital heart defects, multiple types (AD)
BOOBDSV ^a	<i>FLT4</i> (NM_182925.4)	c.89C>G, p.(Pro30Arg)	Missense VUS	0	Predicted damaging (CADD 24.9)	618780	Congenital heart defects, multiple types (AD)
BOOBECK ^a	<i>FLT4</i> (NM_182925.4)	c.482C>T, p.(Ser161Phe)	Missense VUS	0	Predicted damaging (CADD 25.4)	618780	Congenital heart defects, multiple types (AD)
BOODL8L ^a	<i>FLT4</i> (NM_182925.4)	c.2284A>G, p.(Ser762Gly)	Missense VUS	0	Predicted damaging (CADD 24.1)	618780	Congenital heart defects, multiple types (AD)
BO09FTP ^a	<i>NOTCH1</i> (NM_017617.3)	c.4646G>A, p.(Cys1549Tyr)	Missense VUS	0	De novo in Page et al. ¹	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
BO09FNG_R ^a	<i>NOTCH1</i> (NM_017617.3)	c.428C>T, p.(Pro143Leu)	Missense VUS	0	Predicted damaging (CADD 24.7), in three probands	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
BO0BDSY_R ^a	<i>NOTCH1</i> (NM_017617.3)	c.428C>T, p.(Pro143Leu)	Missense VUS	0	Predicted damaging (CADD 24.7), in three probands	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
BO0BDTA ^{a,b}	<i>NOTCH1</i> (NM_017617.3)	c.428C>T, p.(Pro143Leu)	Missense VUS	0	Predicted damaging (CADD 24.7), in three probands	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
BO09G8F ^a	<i>NOTCH1</i> (NM_017617.3)	c.1057C>T, p.(Arg353Cys)	Missense VUS	0	Predicted damaging (CADD 33), in two probands	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
BO0B16Z ^a	<i>NOTCH1</i> (NM_017617.3)	c.1057C>T, p.(Arg353Cys)	Missense VUS	0	Predicted damaging (CADD 33), in two probands	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)

B00B0D6 ^a	<i>NOTCH1</i> (NM_017617.3)	c.5497G>C, p.(Asp1833His)	Missense VUS	0	Predicted damaging (CADD 24.3)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOIB	<i>NOTCH1</i> (NM_017617.3)	c.1687T>C, p.(Cys563Arg)	Missense VUS	0	Predicted damaging (CADD 25.3)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOIH ^a	<i>NOTCH1</i> (NM_017617.3)	c.875G>A, p.(Cys292Tyr)	Missense VUS	0	Predicted damaging (CADD 25.9)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOIW ^a	<i>NOTCH1</i> (NM_017617.3)	c.6011G>T, p.(Arg2004Leu)	Missense VUS	0	Predicted damaging (CADD 33)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOKE ^a	<i>NOTCH1</i> (NM_017617.3)	c.545G>A, p.(Cys182Tyr)	Missense VUS	0	Predicted damaging (CADD 27.6)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOKI ^a	<i>NOTCH1</i> (NM_017617.3)	c.5017G>C, p.(Gly1673Arg)	Missense VUS	0	Predicted damaging (CADD 28.2)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOKR ^a	<i>NOTCH1</i> (NM_017617.3)	c.4428_4430delCGG, p.(Gly1477del)	Other VUS (in-frame deletion)	0	NA	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOM0 ^a	<i>NOTCH1</i> (NM_017617.3)	c.4483C>A, p.(Gln1495Lys)	Missense VUS	0	Predicted damaging (CADD 23.2)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BOSN ^a	<i>NOTCH1</i> (NM_017617.3)	c.1412T>A, p.(Ile471Asn)	Missense VUS	0	Predicted damaging (CADD 25.4)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00B16Y ^a	<i>NOTCH1</i> (NM_017617.3)	c.1934G>A, p.(Cys645Tyr)	Missense VUS	0	Predicted damaging (CADD 27.6)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00B187 ^a	<i>NOTCH1</i> (NM_017617.3)	c.3974C>T, p.(Ala1325Val)	Missense VUS	0	Predicted damaging (CADD 25.2)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BEAA ^{a,b}	<i>NOTCH1</i> (NM_017617.3)	c.3880G>A, p.(Glu1294Lys)	Missense VUS	0	Predicted damaging (CADD 25.2)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BEAD_R ^{a,b}	<i>NOTCH1</i> (NM_017617.3)	c.598G>C, p.(Gly200Arg)	Missense VUS	0	Predicted damaging (CADD 28.6)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00DKZ8 ^a	<i>NOTCH1</i> (NM_017617.3)	c.490T>G, p.(Cys164Gly)	Missense VUS	0	Predicted damaging (CADD 26.8)	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00DKZI_R ^a	<i>NOTCH1</i> (NM_017617.3)	c.436_450dup TCCAACCCCTGCGCC, p.(Ser146_Ala150dup)	Other VUS (in-frame duplication)	0	NA	616028, 109730	Adams-Oliver syndrome (AD), Aortic valve disease (AD)
B00BDSL	<i>JAG1</i> (NM_000214.2)	c.185G>A, p.(Gly62Glu)	Missense VUS	0	Predicted damaging (CADD 22.5)	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD)
B00BESY	<i>JAG1</i> (NM_000214.2)	c.376T>C, p.(Phe126Leu)	Missense VUS	0	Predicted damaging (CADD 33)	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD)
B00BETA	<i>JAG1</i> (NM_000214.2)	c.2365C>T, p.(His789Tyr)	Missense VUS	0	Predicted damaging (CADD 23.3)	187500, 118450	Tetralogy of Fallot (AD), Alagille syndrome (AD)
B00BOSJ	<i>TBX1</i> (NM_080646.1)	c.1095_1101delAGGTGGC, p.(Gly366Valfs*2)	Other VUS (premature stopcodon in the last exon)	0	Does not affect all transcripts	187500	Tetralogy of Fallot (AD)

B00BORM	<i>TBX1</i> (NM_080646.1)	c.607G>C, p.(Gly203Arg)	Missense VUS	0	Predicted damaging (CADD 31)	187500	Tetralogy of Fallot (AD)
B00BEST	<i>TBX1</i> (NM_080646.1)	c.840+5G>A, p.?	Other VUS (intrinsic)	0	Predicted splice effect (CADD 22.8)	187500	Tetralogy of Fallot (AD)
B00DKWP	<i>TBX1</i> (NM_080646.1)	c.956C>G, p.(Ala319Gly)	Missense VUS	0	Predicted damaging (CADD 28)	187500	Tetralogy of Fallot (AD)
B009FZL	<i>DLL4</i> (NM_019074.4)	c.1285C>T, p.(Arg429Cys)	Missense VUS	0	Predicted damaging (CADD 33), in three probands	616589	Adams-Oliver syndrome (AD)
B00BDSW	<i>DLL4</i> (NM_019074.4)	c.1285C>T, p.(Arg429Cys)	Missense VUS	0	Predicted damaging (CADD 33), in three probands	616589	Adams-Oliver syndrome (AD)
B00BDUG	<i>DLL4</i> (NM_019074.4)	c.1285C>T, p.(Arg429Cys)	Missense VUS	0	Predicted damaging (CADD 33), in three probands	616589	Adams-Oliver syndrome (AD)
B009FWD_R	<i>DLL4</i> (NM_019074.4)	c.1240G>A, p.(Gly414Arg)	Missense VUS	0	Predicted damaging (CADD 34)	616589	Adams-Oliver syndrome (AD)
B00BDUC	<i>CHD4</i> (NM_001273.2)	c.4515+1G>T, p.?	LOF VUS	0	Uncertain haplosensitivity of CHD4 ³⁰	617159	Sifrim-Hitz-Weiss syndrome (AD)
B00B0H9	<i>CHD4</i> (NM_001273.2)	c.2084G>A, p.(Arg695Gln)	Missense VUS	0	Predicted damaging (CADD 22.6)	617159	Sifrim-Hitz-Weiss syndrome (AD)
B00BDU2	<i>CHD4</i> (NM_001273.2)	c.4513_4515delAAG, p.(Lys1505del)	Other VUS (in-frame deletion)	0	NA	617159	Sifrim-Hitz-Weiss syndrome (AD)
B00BOJ2	<i>ELN</i> (NM_000501.4)	c.1150+1G>A, p.?	Splice-site VUS	5.69E-05	ELN haploinsufficiency in aortic stenosis and other CHD ³¹	185500	Supravalvar aortic stenosis (AD)
B009FVY_R	<i>ECE1</i> (NM_001397.3)	c.1021-2A>G, p.?	LOF VUS	0	Uncertain haplosensitivity of ECE1	613870	Hirschsprung disease, cardiac defects, and autonomic dysfunction (AD)
B009G7T	<i>CACNA1C</i> (NM_001167625.1)	c.6169G>T, p.(Glu2057*)	LOF VUS	0	Uncertain haplosensitivity of CACNA1C	601005	Timothy syndrome (AD)
B009G10_R	<i>TLL1</i> (NM_001204760.1)	c.1159-2A>C, p.?	LOF VUS	2.00E-04	Uncertain haplosensitivity of TLL1	613087	Atrial septal defect (AD)
B009FT1	<i>TLL1</i> (NM_001204760.1)	c.713T>C, p.(Val238Ala)	Missense VUS	2.00E-04	Predicted damaging (CADD 22.7) ³² , in two probands	613087	Atrial septal defect (AD)
B00B160_R	<i>TLL1</i> (NM_001204760.1)	c.713T>C, p.(Val238Ala)	Missense VUS	2.00E-04	Predicted damaging (CADD 22.7) ³² , in two probands	613087	Atrial septal defect (AD)

TOF clinical variants & interacting network
Supplementary material

B009G8X	<i>CRELD1</i> (NM_001077415.2)	c.959delA, p.(Gln320Argfs*25)	LOF VUS	3.00E-04	Uncertain haplosensitivity of <i>CRELD1</i>	606217	Atrioventricular septal defect, partial, with heterotaxy syndrome (AD)
B00BOKJ ^b	<i>CRELD1</i> (NM_001077415.2)	c.977_984dupGCGGTTAT, p.(Arg329Alafs*19)	LOF VUS	5.28E-05	Uncertain haplosensitivity of <i>CRELD1</i>	606217	Atrioventricular septal defect, partial, with heterotaxy syndrome (AD)
B00BDUD	<i>CRELD1</i> (NM_001077415.2)	c.484C>G, p.(Pro162Ala)	Missense VUS	0	Predicted damaging ³³	606217	Atrioventricular septal defect, partial, with heterotaxy syndrome (AD)
B00BOT7	<i>SMAD6</i> (NM_005585.5)	c.223C>T, p.(Arg75*)	LOF VUS	0	Uncertain haplosensitivity of <i>SMAD6</i>	179300, 614823, 617439	Radioulnar synostosis, nonsyndromic (AD), Aortic valve disease (AD), Craniosynostosis (AD)
B009FTM	<i>PRKD1</i> (NM_002742.2)	c.2241delC, p.(Ala748Leufs*8)	LOF VUS	0	Uncertain haplosensitivity of <i>PRKD1</i>	617364	Congenital heart defects and ectodermal dysplasia (AD)
B009G10_R	<i>PRKD1</i> (NM_002742.2)	c.802A>T, p.(Lys268*)	LOF VUS	2.44E-05	Uncertain haplosensitivity of <i>PRKD1</i>	617364	Congenital heart defects and ectodermal dysplasia (AD)
B00BET4	<i>GLI3</i> (NM_000168.6)	c.2119C>T, p.(Pro707Ser)	Missense VUS	3.00E-04	Predicted damaging ³⁴	146510	Pallister-Hall syndrome (AD)
B00DKW1	<i>KANSL1</i> (NM_001193466.2)	c.190C>T, p.(Arg64*)	Other VUS (premature stopcodon in the last exon)	4.06E-06	NA	610443	Koolen-De Vries syndrome (AD)
B009FR7_R	<i>MYH6</i> (NM_002471.3)	c.642+1G>T, p.?	LOF VUS	0	Uncertain haplosensitivity of <i>MYH6</i>	614089	Atrial septal defect
B009FNJ_R	<i>NKX2-6</i> (NM_001136271.2)	c.797delG, p.(Gly266Valfs*?)	LOF VUS	0	Uncertain haplosensitivity of <i>NKX2-6</i>	217095	Conotruncal heart malformations, Persistent truncus arteriosus
B009G3M_R	<i>NKX2-6</i> (NM_001136271.2)	c.274+1G>A, p.?	LOF VUS	0	Uncertain haplosensitivity of <i>NKX2-6</i>	217095	Conotruncal heart malformations, Persistent truncus arteriosus
B009G8Y	<i>NKX2-6</i> (NM_001136271.2)	c.455dupA, p.(Gln153Alafs*?)	LOF VUS	3.28E-05	Uncertain haplosensitivity of <i>NKX2-6</i>	217095	Conotruncal heart malformations, Persistent truncus arteriosus
B00BOL0	<i>NKX2-6</i> (NM_001136271.2)	c.455dupA, p.(Gln153Alafs*?)	LOF VUS	3.28E-05	Uncertain haplosensitivity of <i>NKX2-6</i>	217095	Conotruncal heart malformations, Persistent truncus arteriosus
B00DL8V	<i>TAB2</i> (NM_001292034.3)	c.688C>A, p.(Gln230Lys)	Missense VUS	1.63E-05	Predicted damaging ³⁵	614980	Congenital heart defects, nonsyndromic (AD)

BOOBOSL	<i>TBX20</i> (NM_001077653.2)	c.456C>G, p.(Ile152Met)	Missense VUS	2.03E-05	Predicted damaging ³⁶	611363	Atrial septal defect
VUS in CHD candidate genes							
BOOBOKS	<i>KDR</i> (NM_002253.2)	c.3817G>T, p.(Glu1273*)	Other VUS (premature stopcodon in the penultimate exon)	4.07E-06	NA	NA	23, 24
BOOBORT_R	<i>KDR</i> (NM_002253.2)	c.2248G>C, p.(Ala750Pro)	Missense VUS	0	Predicted damaging (CADD 21.9)	NA	23, 24
BOOBEB6	<i>KDR</i> (NM_002253.2)	c.2234G>C, p.(Cys745Ser)	Missense VUS	0	Predicted damaging (CADD 25.4)	NA	23, 24
BOODL8L	<i>KDR</i> (NM_002253.2)	c.358G>C, p.(Asp120His)	Missense VUS	0	Predicted damaging (CADD 34)	NA	23, 24
BOOB16V	<i>IQGAP1</i> (NM_003870.3)	c.641A>G, p.(Glu214Gly)	Missense VUS	0	Predicted damaging (CADD 28.8)	NA	23, 25, 26
BOOBDSJ_R	<i>IQGAP1</i> (NM_003870.3)	c.3887A>G, p.(Tyr1296Cys)	Missense VUS	0	Predicted damaging (CADD 32)	NA	23, 25, 26
BOODLDA	<i>IQGAP1</i> (NM_003870.3)	c.353A>C, p.(Gln118Pro)	Missense VUS	0	Predicted damaging (CADD 24.6)	NA	23, 25, 26
BOOBET7	<i>VEGFA</i> (NM_001171623.1)	c.28delT, p.(Trp10Glyfs*32)	LOF VUS	0	VEGFA dysregulation in mouse models with TOF, candidate gene in humans with TOF	NA	23,37
BO009FQG_R	<i>BCAR1</i> (NM_001170715.1)	c.1957C>T, p.(Arg653*)	LOF VUS	0	Candidate gene for TOF	NA	23
BO009FWJ_R	<i>KIRREL3</i> (NM_032531.3)	c.634delC, p.(Leu212Serfs*105)	LOF VUS	0	In Jacobsen syndrome critical region	NA	NA
BO009FUS_R	<i>LTBP3</i> (NM_001130144.2)	c.3376_3377delAG, p.(Ser1126Profs*85)	LOF VUS	0	Uncertain haplosensitivity of LTBP3, associated with cardiac defects ³⁸	617809	Geleophysic dysplasia (AD)
BOOBODN_R	<i>LTBP3</i> (NM_001130144.2)	c.1075delT, p.(Cys359Alafs*29)	LOF VUS	4.06E-06	Uncertain haplosensitivity of LTBP3, associated with cardiac defects ³⁸	617809	Geleophysic dysplasia (AD)
BOOBOE9	<i>ZFPM1</i> (NM_153813.2)	c.886delC, p.(Gln296Serfs*28)	LOF VUS	0	Candidate gene for TOF	NA	39
BOOBOKF	<i>ZFPM1</i> (NM_153813.2)	c.1614dupC, p.(Ala539Argfs*133)	LOF VUS	2.55E-05	Candidate gene TOF	NA	39
BOOBONS_R	<i>MESP1</i> (NM_018670.3)	c.310G>T, p.(Glu104*)	LOF VUS	6.28E-05	Candidate gene for TOF	NA	40, 41

B00B16X	<i>MESP1</i> (NM_018670.3)	c.370G>T, p.(Glu124*)	LOF VUS	4.99E-05	Candidate gene for TOF	NA	40, 41
---------	-------------------------------	-----------------------	---------	----------	------------------------	----	--------

All variants were heterozygous. Minor allele frequencies (MAF) were derived from gnomAD_exomes_All.

^a Variant also reported in Page et al.¹. Reporting of *NOTCH1*, *FLT4* and other variants may differ on the basis of differences in methodology of the current study to that of Page et al. ¹, e.g., nomenclature, frequency cut-offs, in silico prediction methods, exclusion of samples (see Discussion in manuscript text).

^b Individuals with other likely pathogenic variants (Table S2, S3).

LOF, loss-of-function; NA, Not available; VUS, variant of uncertain significance.

Table S6. Other very rare, pathogenic/likely pathogenic variants in 7 genes for childhood-onset disorders (n = 8 loss-of-function, n = 1 missense), but with uncertain relevance currently to TOF.

Sample	Gene	Variant	Variant type	MAF	Disease mechanism/evidence	OMIM-P #	OMIM disease (inheritance) or supporting literature
B00DKWN	<i>TCF12</i> ^b (NM_207037.1)	c.556delG, p.(Val186Cysfs*59)	LOF	0	TCF12 haploinsufficiency	615314	Craniosynostosis (AD), ²⁴
B00BOKJ	<i>TCF12</i> ^b (NM_207037.1)	c.1640_1641delAA, p.(Lys547Argfs*4)	LOF	0	TCF12 haploinsufficiency	615314	Craniosynostosis (AD), ²⁴
B00B1CK	<i>POLR1A</i> ^b (NM_015425.6)	c.5062+1G>C, p.?	LOF	0	POLR1A haploinsufficiency	616462	Acrofacial dysostosis, Cincinnati type (AD), ⁴²
B00BEAR	<i>POLR1A</i> ^b (NM_015425.6)	c.3394C>T, p.(Arg1132*)	LOF	0	POLR1A haploinsufficiency	616462	Acrofacial dysostosis, Cincinnati type (AD), ⁴²
B00BDSE	<i>GLI2</i> ^b (NM_005270.5)	c.2293+1G>C, p.?	LOF	0	GLI2 haploinsufficiency	615849, 610829	Culler-Jones syndrome (AD), Holoprosencephaly (AD)
B00DLOI	<i>APC</i> ^b (NM_000038.6)	c.1213C>T, p.(Arg405*)	LOF	0	APC haploinsufficiency	175100	Adenomatous polyposis coli (AD)
B00B15G	<i>EDA</i> (NM_001399.5)	c.466C>T, p.(Arg156Cys)	Missense	0	De novo in Montreal et al. ⁴³	313500	Tooth agenesis, selective, X-linked 1 (XLD)
B00BOK7	<i>ZMYND11</i> (NM_006624.5)	c.1203_1206delTCAA, p.(Asn401Lysfs*17)	LOF	0	ZMYND11 haploinsufficiency	616083	Mental retardation (AD)
B00BEAF ^a	<i>TRIO</i> (NM_007118.2)	c.3217dupG, p.(Ala1073Glyfs*34)	LOF	0	TRIO haploinsufficiency	617061	Intellectual developmental disorder, with microcephaly (AD)

All variants were heterozygous. Minor allele frequencies (MAF) were derived from gnomAD_exomes_All.

^a Individual with another likely pathogenic variant in *SCN5A* with potential implications for cardiovascular outcome (Table S7).

^b Despite their uncertain relevance to TOF, the encoded proteins connect to the network map of TOF predisposing genes/proteins (Figure 2): GLI2 (NOTCH1, SMAD2, JAG1, PSMD12), APC (NOTCH1, IQGAP1, PSMD12, CSNK2A1), TCF12 (NOTCH1, SMAD2, EP300), POLR1A (EP300).

AD, autosomal dominant; LOF, loss-of-function; XLD, X-linked dominant.

Table S7. Pathogenic/likely pathogenic variants (n = 16) with potential implications to cardiovascular outcome and management.

Sample	Gene	Variant	Variant interpretation	MAF	Disease	Cardiovascular risk	
						CHD	Other outcomes
Variants considered causative for the CHD (as presented in Table S2)							
B00BOLX	<i>LZTR1</i> (NM_006767.4)	c.742G>A, p.(Gly248Arg)	Pathogenic	0	Noonan syndrome	TOF, pulmonary valve stenosis, septal defects, aortic coarctation, and other CHD ⁴⁴	Cardiac hypertrophy
B009FV4	<i>RAF1</i> (NM_001354689.3)	c.1532C>T, p.(Thr511Ile)	Pathogenic	0		TOF, patent ductus arteriosus, patent foramen ovale, septal defects ²⁰	
B009FVM_R	<i>CACNA1C</i> (NM_001167625.1)	c.1216G>A, p.(Gly406Arg)	Pathogenic	0	Timothy syndrome	Arrhythmias, cardiac hypertrophy/dysfunction, sudden cardiac death	
BOOBEAD_R	<i>NF1</i> (NM_000267.3)	c.5206-1G>C, p.?	Likely pathogenic	0	Neurofibromatosis	TOF and other CHD	Cardiac hypertrophy, pulmonary hypertension, intracardiac neurofibroma, arterial hypertension, strokes
B009G7Z	<i>RASA1</i> (NM_002890.3)	c.2150_2151delTC, p.(Ile717Asnfs*8)	Likely pathogenic	0	Capillary malformation-arteriovenous malformation syndrome	TOF and other CHD ¹⁴	Cardiac overload/heart failure due to arteriovenous malformations/fistulas
Other cardiac risk variants							
B00BDVA	<i>MYBPC3</i> (NM_000256.3)	c.1483C>G, p.(Arg495Gly)	Likely pathogenic	4.06E-06	Hypertrophic cardiomyopathy	Unknown	Cardiac hypertrophy, arrhythmias, heart failure, sudden cardiac death
BOOBOSE ^a	<i>MYBPC3</i> (NM_000256.3)	c.1504C>T, p.(Arg502Trp)	Pathogenic	4.87E-05			
B00DLDV	<i>MYBPC3</i> (NM_000256.3)	c.3288delG, p.(Glu1096Aspfs*93)	Pathogenic	0			
BOOBET1	<i>MYH7</i> (NM_000257.4)	c.2594A>G, p.(Lys865Arg)	Likely pathogenic	4.06E-06			
B00BOHU	<i>MYL2</i> (NM_000432.4)	c. 64G>A, p.(Glu22Lys)	Likely pathogenic	2.03E-05			
B00BDUN	<i>TNNI3</i> (NM_000363.5)	c.484C>T, p.(Arg162Trp)	Likely pathogenic	4.07E-05	Arrhythmogenic right ventricular cardiomyopathy	Unknown	Arrhythmias, heart failure, sudden cardiac death
B00BOJX	<i>DSC2</i> (NM_024422.6)	c.501_502delTA, p.(Thr168Hisfs*11)	Likely pathogenic	0			
B00B178	<i>DSP</i> (NM_004415.4)	c.7756C>T, p.(Arg2586*)	Likely pathogenic	0			
B00BDS5	<i>DSP</i> (NM_004415.4)	c.8077_8080delAAAG, p.(Lys2693Profs*3)	Likely pathogenic	0			
B00B0D3	<i>DMD</i> (NM_000109.4)	c.1789-1G>C, p.?	Likely pathogenic	0	Dilated cardiomyopathy	Unknown	Cardiac dilation, arrhythmias

BOOBEA ^a	<i>SCN5A</i> (NM_198056.2)	c.2692G>T, p.(Glu898*)	Likely pathogenic	0	Brugada syndrome	Unknown	Arrhythmias, sudden cardiac death
---------------------	-------------------------------	------------------------	-------------------	---	------------------	---------	-----------------------------------

All variants were heterozygous. Minor allele frequencies (MAF) were derived from gnomAD_exomes_All.

^a Individuals with additional likely pathogenic variants (Tables S2, S6).




Figure S1. Variants identified in vascular endothelial growth factor receptor 2 (VEGFR2; KDR: NM_002253.2), in patients with TOF or other conotruncal defects.

Loss-of-function variants (black, top); in-frame deletion, missense variants, and stopgain variant in penultimate exon (gray, bottom).

Variants from this study (Tables S3 and S5) are in ***bold/italics***.

Variants reported in Jin et al.²⁸, Table S7: p.(Lys529*), c.1646-2A>T.

Variants reported in Reuter et al.²³, Figure 1: p.(Arg880*), p.(Trp1096*), p.(Glu407del), p.(Arg833Trp), p.(Ala1030Thr).

Variants reported in Morton et al.²⁴, Table S4 (some probands may also be reported in / overlap those reported by Jin et al.): p.(Gln268*), p.(Lys529*), c.1646-2A>T, p.(Gln697*), c.3070-2A>G, p.(Lys1110*).




Figure S2. Confirmed and candidate genes, identified for tetralogy of Fallot (two cohorts), encode functionally interacting proteins – extended network. In addition to using rare high-impact variant data from the $n = 811$ TOF exomes from EGAS00001003302¹ (Tables S2, S3, Figure 2), this network also considers likely pathogenic loss-of-function variants available from an independent sample of $n = 424$ TOF exomes from Jin et al.²⁸ (Table S4). Network analysis was performed using Cytoscape, STRING and the total 30 CHD genes with clinically relevant variants identified in the two samples (Tables S2, S3, S4; STRING interaction enrichment p value = 1.0E-15). Node sizes (circles) represent the connectivity (numbers of edges to other proteins). Node greyscales represent the degree of expression from the Gene Expression Omnibus (GEO) database (heart tissue). Edge widths represent the confidence (strength of data support). VEGFR2 (gene *KDR*) and NOTCH1 form central nodes within the network, each connecting directly with 11 or 12 other proteins, respectively. NOTCH2 adds 5 interactions to the extended network, compared to the one presented in Figure 2, for the original $n = 811$ probands with TOF.




Figure S3. Pathway enrichment map of confirmed genes (n = 23) and emerging candidate genes (n = 3) for CHD/TOF identified in n = 811 individuals with TOF. P values and odd ratios are reported in Table S8 (provided as a separate file).

Supplementary references:

1. Page DJ, Miossec MJ, Williams SG, Monaghan RM, Fotiou E, Cordell HJ, Sutcliffe L, Topf A, Bourgey M, Bourque G, Eveleigh R, Dunwoodie SL, Winlaw DS, Bhattacharya S, Breckpot J, Devriendt K, Gewillig M, Brook JD, Setchfield KJ, Bu'Lock FA, O'Sullivan J, Stuart G, Bezzina CR, Mulder BJM, Postma AV, Bentham JR, Baron M, Bhaskar SS, Black GC, Newman WG, Hentges KE, Lathrop GM, Santibanez-Koref M and Keavney BD. Whole Exome Sequencing Reveals the Major Genetic Contributors to Nonsyndromic Tetralogy of Fallot. *Circ Res*. 2019;124:553-563.
2. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25:1754-60.
3. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D and Daly MJ. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43:491-8.
4. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S and DePristo MA. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics*. 2013;43:11 10 1-33.
5. Wang K, Li M and Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38:e164.
6. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG and Exome Aggregation C. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536:285-91.
7. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Vallabh Minikel E, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ and MacArthur DG. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv*. 2019;531210.
8. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM and Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*. 2000;25:25-9.
9. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu

- G, Stein L, Hermjakob H and D'Eustachio P. The reactome pathway knowledgebase. *Nucleic Acids Res.* 2020;48:D498-D503.
10. Kanehisa M and Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000;28:27-30.
11. Allen HL, Flanagan SE, Shaw-Smith C, De Franco E, Akerman I, Caswell R, International Pancreatic Agenesis C, Ferrer J, Hattersley AT and Ellard S. GATA6 haploinsufficiency causes pancreatic agenesis in humans. *Nat Genet.* 2011;44:20-22.
12. Pierson TM, Otero MG, Grand K, Choi A, Graham JM, Jr., Young JI and Mackay JP. The NuRD complex and macrocephaly associated neurodevelopmental disorders. *Am J Med Genet C Semin Med Genet.* 2019;181:548-556.
13. Mirzaa G, Conway R, Graham JM, Jr. and Dobyns WB. PIK3CA-Related Segmental Overgrowth. In: M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens and A. Amemiya, eds. *GeneReviews(R)* Seattle (WA); 1993.
14. Bayrak-Toydemir P and Stevenson DA. Capillary Malformation-Arteriovenous Malformation Syndrome. In: M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens and A. Amemiya, eds. *GeneReviews(R)* Seattle (WA); 1993.
15. Mohapatra B, Casey B, Li H, Ho-Dawson T, Smith L, Fernbach SD, Molinari L, Niesh SR, Jefferies JL, Craigen WJ, Towbin JA, Belmont JW and Ware SM. Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. *Hum Mol Genet.* 2009;18:861-71.
16. De Luca A, Sarkozy A, Consoli F, Ferese R, Guida V, Dentici ML, Mingarelli R, Bellacchio E, Tuo G, Limongelli G, Digilio MC, Marino B and Dallapiccola B. Familial transposition of the great arteries caused by multiple mutations in laterality genes. *Heart.* 2010;96:673-7.
17. Granadillo JL, Chung WK, Hecht L, Corsten-Janssen N, Wegner D, Nij Bijvank SWA, Toler TL, Pineda-Alvarez DE, Douglas G, Murphy JJ, Shimony J and Shinawi M. Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants. *Hum Mutat.* 2018;39:1875-1884.
18. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown KK, Carrier NJ, Cheung YH, Deanfield J, DePalma S, Fakhro KA, Glessner J, Hakonarson H, Italia MJ, Kaltman JR, Kaski J, Kim R, Kline JK, Lee T, Leipzig J, Lopez A, Mane SM, Mitchell LE, Newburger JW, Parfenov M, Pe'er I, Porter G, Roberts AE, Sachidanandam R, Sanders SJ, Seiden HS, State MW, Subramanian S, Tikhonova IR, Wang W, Warburton D, White PS, Williams IA, Zhao H, Seidman JG, Brueckner M, Chung WK, Gelb BD, Goldmuntz E, Seidman CE and Lifton RP. De novo mutations in histone-modifying genes in congenital heart disease. *Nature.* 2013;498:220-3.
19. Meester JAN, Sukalo M, Schroder KC, Schanze D, Baynam G, Borck G, Bramswig NC, Duman D, Gilbert-Dussardier B, Holder-Espinasse M, Itin P, Johnson DS, Joss S, Koillinen H, McKenzie F, Morton J, Nelle H, Reardon W, Roll C, Salih MA, Savarirayan R, Scurr I, Splitt M, Thompson E, Titheradge H, Travers CP, Van Maldergem L, Whiteford M, Wieczorek D, Vandeweyer G, Trembath R, Van Laer L, Loeys BL, Zenker M, Southgate L and Wuys W. Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort. *Hum Mutat.* 2018;39:1246-1261.
20. Napolitano C, Splawski I, Timothy KW, Bloise R and Priori SG. Timothy Syndrome. In: M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens and A. Amemiya, eds. *GeneReviews(R)* Seattle (WA); 1993.
21. Clinton J, Huckstadt V, Mucciolo M, Lepri F, Novelli A, Gravina LP and Obregon MG. Providing more evidence on LZTR1 variants in Noonan syndrome patients. *Am J Med Genet A.* 2020;182:409-414.
22. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N, Neidich J, Monaghan KG, McKnight D, Bai R, Suchy S, Friedman B, Tahiliani J, Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK and Bale S. Clinical application of whole-exome sequencing across clinical indications. *Genet Med.* 2016;18:696-704.

23. Reuter MS, Jobling R, Chaturvedi RR, Manshaei R, Costain G, Heung T, Curtis M, Hosseini SM, Liston E, Lowther C, Oechslin E, Sticht H, Thiruvahindrapuram B, Mil SV, Wald RM, Walker S, Marshall CR, Silversides CK, Scherer SW, Kim RH and Bassett AS. Haploinsufficiency of vascular endothelial growth factor related signaling genes is associated with tetralogy of Fallot. *Genet Med.* 2019;21:1001-1007.
24. Morton SU, Shimamura A, Newburger PE, Opotowsky AR, Quiat D, Pereira AC, Jin SC, Gurvitz M, Brueckner M, Chung WK, Shen Y, Bernstein D, Gelb BD, Giardini A, Goldmuntz E, Kim RW, Lifton RP, Porter GA, Jr., Srivastava D, Tristani-Firouzi M, Newburger JW, Seidman JG and Seidman CE. Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease. *JAMA Cardiol.* 2020.
25. Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, Spiegel E, Brennan K, Stong N, Jobanputra V, Ren Z, Zhu X, Mebane C, Nahum O, Wang Q, Kamalakaran S, Malone C, Anyane-Yeboa K, Miller R, Levy B, Goldstein DB and Wapner RJ. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. *Lancet.* 2019;393:758-767.
26. Sevim Bayrak C, Zhang P, Tristani-Firouzi M, Gelb BD and Itan Y. De novo variants in exomes of congenital heart disease patients identify risk genes and pathways. *Genome Med.* 2020;12:9.
27. Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Towbin J, Belmont JW, Baxevanis AD, Schier AF and Muenke M. Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans. *Am J Hum Genet.* 2007;81:987-94.
28. Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, Zeng X, Qi H, Chang W, Sierant MC, Hung WC, Haider S, Zhang J, Knight J, Bjornson RD, Castaldi C, Tikhonova IR, Bilguvar K, Mane SM, Sanders SJ, Mital S, Russell MW, Gaynor JW, Deanfield J, Giardini A, Porter GA, Jr., Srivastava D, Lo CW, Shen Y, Watkins WS, Yandell M, Yost HJ, Tristani-Firouzi M, Newburger JW, Roberts AE, Kim R, Zhao H, Kaltman JR, Goldmuntz E, Chung WK, Seidman JG, Gelb BD, Seidman CE, Lifton RP and Brueckner M. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. *Nat Genet.* 2017;49:1593-1601.
29. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL and Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17:405-24.
30. Weiss K, Lazar HP, Kurolap A, Martinez AF, Paperna T, Cohen L, Smeland MF, Whalen S, Heide S, Keren B, Terhal P, Irving M, Takaku M, Roberts JD, Petrovich RM, Schrier Vergano SA, Kenney A, Hove H, DeChene E, Quinonez SC, Colin E, Ziegler A, Rumple M, Jain M, Monteil D, Roeder ER, Nugent K, van Haeringen A, Gambello M, Santani A, Medne L, Krock B, Skraban CM, Zackai EH, Dubbs HA, Smol T, Ghoumid J, Parker MJ, Wright M, Turnpenny P, Clayton-Smith J, Metcalfe K, Kurumizaka H, Gelb BD, Baris Feldman H, Campeau PM, Muenke M, Wade PA and Lachlan K. The CHD4-related syndrome: a comprehensive investigation of the clinical spectrum, genotype-phenotype correlations, and molecular basis. *Genet Med.* 2020;22:389-397.
31. Fahed AC, Gelb BD, Seidman JG and Seidman CE. Genetics of congenital heart disease: the glass half empty. *Circ Res.* 2013;112:707-20.
32. Stanczak P, Witecka J, Szydlo A, Gutmajster E, Lisik M, Augusciak-Duma A, Tarnowski M, Czekaj T, Czekaj H and Sieron AL. Mutations in mammalian tolloid-like 1 gene detected in adult patients with ASD. *Eur J Hum Genet.* 2009;17:344-51.
33. Zatyka M, Priestley M, Ladusans EJ, Fryer AE, Mason J, Latif F and Maher ER. Analysis of CRELD1 as a candidate 3p25 atrioventricular septal defect locus (AVSD2). *Clin Genet.* 2005;67:526-8.
34. Wild A, Kalff-Suske M, Vortkamp A, Bornholdt D, Konig R and Grzeschik KH. Point mutations in human GLI3 cause Greig syndrome. *Hum Mol Genet.* 1997;6:1979-84.

35. Thienpont B, Zhang L, Postma AV, Breckpot J, Tranchevent LC, Van Loo P, Mollgard K, Tommerup N, Bache I, Turner Z, van Engelen K, Menten B, Mortier G, Waggoner D, Gewillig M, Moreau Y, Devriendt K and Larsen LA. Haploinsufficiency of TAB2 causes congenital heart defects in humans. *Am J Hum Genet.* 2010;86:839-49.
36. Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, Castro ML, Butler TL, Hyun C, Guo G, Otway R, Mackay JP, Waddell LB, Cole AD, Hayward C, Keogh A, Macdonald P, Griffiths L, Fatkin D, Sholler GF, Zorn AM, Feneley MP, Winlaw DS and Harvey RP. Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. *Am J Hum Genet.* 2007;81:280-91.
37. van den Akker NM, Molin DG, Peters PP, Maas S, Wisse LJ, van Brempt R, van Munsteren CJ, Bartelings MM, Poelmann RE, Carmeliet P and Gittenberger-de Groot AC. Tetralogy of fallot and alterations in vascular endothelial growth factor-A signaling and notch signaling in mouse embryos solely expressing the VEGF120 isoform. *Circ Res.* 2007;100:842-9.
38. Intarak N, Theerapanon T, Thaweesapphitak S, Suphapeetiporn K, Porntaveetus T and Shotelersuk V. Genotype-phenotype correlation and expansion of orodental anomalies in LTBP3-related disorders. *Mol Genet Genomics.* 2019;294:773-787.
39. Walton RZ, Bruce AE, Olivey HE, Najib K, Johnson V, Earley JU, Ho RK and Svensson EC. Fog1 is required for cardiac looping in zebrafish. *Dev Biol.* 2006;289:482-93.
40. Werner P, Latney B, Deardorff MA and Goldmuntz E. MESP1 Mutations in Patients with Congenital Heart Defects. *Hum Mutat.* 2016;37:308-14.
41. Lahm H, Deutsch MA, Dressen M, Doppler S, Werner A, Horer J, Cleuziou J, Schreiber C, Bohm J, Laugwitz KL, Lange R and Krane M. Mutational analysis of the human MESP1 gene in patients with congenital heart disease reveals a highly variable sequence in exon 1. *Eur J Med Genet.* 2013;56:591-8.
42. Weaver KN, Watt KE, Hufnagel RB, Navajas Acedo J, Linscott LL, Sund KL, Bender PL, Konig R, Lourenco CM, Hehr U, Hopkin RJ, Lohmann DR, Trainor PA, Wieczorek D and Saal HM. Acrofacial Dysostosis, Cincinnati Type, a Mandibulofacial Dysostosis Syndrome with Limb Anomalies, Is Caused by POLR1A Dysfunction. *Am J Hum Genet.* 2015;96:765-74.
43. Montreal AW, Zonana J and Ferguson B. Identification of a new splice form of the EDA1 gene permits detection of nearly all X-linked hypohidrotic ectodermal dysplasia mutations. *Am J Hum Genet.* 1998;63:380-9.
44. Roberts AE, Allanson JE, Tartaglia M and Gelb BD. Noonan syndrome. *Lancet.* 2013;381:333-42.